ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral injection in phase 2 clinical trials both in China and the US.
According to the Chinese pharma company, the US phase 2a portion of the study has two parts, of which the first is the evaluation of MVR-T3011 as a single agent for melanoma and metastatic solid tumors. In the second part, MVR-T3011 will be evaluated in combination with pembrolizumab for the treatment of non-small-cell lung carcinoma.
On the other hand, the Chinese phase 2a study is evaluating MVR-T3011 as a single agent for the treatment of head and neck cancer, breast cancer, and sarcoma.
MVR-T3011 is a genetically modified oncolytic herpes simplex virus (oHSV). It is said to incorporate a couple of exogenous genes – PD-1 antibody and IL-12 which further boost immune responses, said ImmVira.
Phase 1 clinical trials of MVR-T3011 began in China in April 2020 and had started in the US and Australia in September 2020. Data gathered from the preliminary phase 1 clinical studies had shown a favorable safety profile and promising efficacy profile, said the Chinese pharma company.